获得批准-话题@MedSci

#获得批准#

16篇内容 | 229人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1811425, encodeId=48ca1811425a4, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=Valneva的COVID-19疫苗在英国首次获得批准, objectType=article, longId=724525, objectId=3db3e2452558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3db3e2452558, replyNumber=0, likeNumber=31, createdTime=2022-05-27, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3db3e2452558, moduleTitle=Valneva的COVID-19疫苗在英国首次获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3db3e2452558)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811424, encodeId=45551811424c1, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=百济神州的tislelizumab在中国再次获得批准, objectType=article, longId=724435, objectId=fa20e24435c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa20e24435c4, replyNumber=0, likeNumber=30, createdTime=2023-01-22, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa20e24435c4, moduleTitle=百济神州的tislelizumab在中国再次获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa20e24435c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811422, encodeId=bc81181142248, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=警惕糖尿病相关低血糖症！新型疗法Zegalogue在美国获得批准, objectType=article, longId=209078, objectId=ca332090e834, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca332090e834, replyNumber=0, likeNumber=41, createdTime=2022-02-24, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca332090e834, moduleTitle=警惕糖尿病相关低血糖症！新型疗法Zegalogue在美国获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca332090e834)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811423, encodeId=61b21811423b1, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=SpeeDx的新冠病毒诊断检测系统获得批准, objectType=article, longId=215665, objectId=b8ed215665a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ed215665a0, replyNumber=0, likeNumber=36, createdTime=2021-09-25, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ed215665a0, moduleTitle=SpeeDx的新冠病毒诊断检测系统获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ed215665a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811421, encodeId=6e8b1811421aa, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=Emgality（galcanezumab）治疗阵发性丛集性头痛：已在加拿大获得批准, objectType=article, longId=207661, objectId=8a1820e661cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1820e661cb, replyNumber=0, likeNumber=36, createdTime=2021-11-24, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1820e661cb, moduleTitle=Emgality（galcanezumab）治疗阵发性丛集性头痛：已在加拿大获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a1820e661cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811420, encodeId=d2c0181142040, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=Dupixent在欧盟获得批准用于儿童特应性皮炎, objectType=article, longId=203948, objectId=a74e203948f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a74e203948f7, replyNumber=0, likeNumber=30, createdTime=2021-11-05, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a74e203948f7, moduleTitle=Dupixent在欧盟获得批准用于儿童特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a74e203948f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811417, encodeId=9265181141e67, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, objectType=article, longId=199343, objectId=af9d1993432d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af9d1993432d, replyNumber=0, likeNumber=19, createdTime=2020-08-18, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af9d1993432d, moduleTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af9d1993432d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811413, encodeId=f15b1811413de, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌, objectType=article, longId=188190, objectId=a74718819031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a74718819031, replyNumber=0, likeNumber=25, createdTime=2020-10-30, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a74718819031, moduleTitle=喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a74718819031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811419, encodeId=0d67181141914, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准, objectType=article, longId=200277, objectId=dacc2002e766, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dacc2002e766, replyNumber=0, likeNumber=30, createdTime=2021-08-07, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dacc2002e766, moduleTitle=NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dacc2002e766)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811418, encodeId=f5c7181141810, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=Vericiguat有望在中国获得批准，用于治疗慢性心衰, objectType=article, longId=200045, objectId=1c8f200045f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8f200045f3, replyNumber=0, likeNumber=29, createdTime=2021-03-23, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8f200045f3, moduleTitle=Vericiguat有望在中国获得批准，用于治疗慢性心衰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8f200045f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811414, encodeId=5b551811414c3, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=默克公司的埃博拉疫苗Ervebo在四个非洲国家获得批准, objectType=article, longId=188483, objectId=16e7188483ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16e7188483ae, replyNumber=0, likeNumber=29, createdTime=2020-11-01, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16e7188483ae, moduleTitle=默克公司的埃博拉疫苗Ervebo在四个非洲国家获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16e7188483ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811416, encodeId=3ccf18114169a, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, objectType=article, longId=199330, objectId=176519933069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=176519933069, replyNumber=0, likeNumber=27, createdTime=2021-01-05, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=176519933069, moduleTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=176519933069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, objectType=article, longId=194256, objectId=5af31942566d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af31942566d, replyNumber=0, likeNumber=42, createdTime=2020-07-28, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af31942566d, moduleTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af31942566d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811412, encodeId=228c18114129f, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=我国DNA疫苗获得批准, objectType=article, longId=139577, objectId=ee081395e7e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee081395e7e8, replyNumber=0, likeNumber=34, createdTime=2018-12-20, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee081395e7e8, moduleTitle=我国DNA疫苗获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee081395e7e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811411, encodeId=0281181141135, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=[药企软文]重磅！美罗华生物仿制药在欧洲获得批准, objectType=article, longId=90445, objectId=632a904456c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632a904456c, replyNumber=0, likeNumber=0, createdTime=2017-12-11, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632a904456c, moduleTitle=[药企软文]重磅！美罗华生物仿制药在欧洲获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632a904456c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1811410, encodeId=dc971811410a7, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, objectTitle=含佐剂H5N1疫苗首次获得批准, objectType=article, longId=27210, objectId=97eb2e21075, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97eb2e21075, replyNumber=0, likeNumber=27, createdTime=2014-06-01, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97eb2e21075, moduleTitle=含佐剂H5N1疫苗首次获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97eb2e21075)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

获得批准

2020-05-29

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

Valneva的COVID-19疫苗在英国首次获得批准

2022-05-27

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

百济神州的tislelizumab在中国再次获得批准

2023-01-22

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

警惕糖尿病相关低血糖症！新型疗法Zegalogue在美国获得批准

2022-02-24

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

SpeeDx的新冠病毒诊断检测系统获得批准

2021-09-25

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

Emgality（galcanezumab）治疗阵发性丛集性头痛：已在加拿大获得批准

2021-11-24

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

Dupixent在欧盟获得批准用于儿童特应性皮炎

2021-11-05

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌

2020-08-18

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌

2020-10-30

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准

2021-08-07

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

Vericiguat有望在中国获得批准，用于治疗慢性心衰

2021-03-23

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

默克公司的埃博拉疫苗Ervebo在四个非洲国家获得批准

2020-11-01

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准

2021-01-05

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准

2020-07-28

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

我国DNA疫苗获得批准

2018-12-20

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

[药企软文]重磅！美罗华生物仿制药在欧洲获得批准

2017-12-11

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#获得批准#

含佐剂H5N1疫苗首次获得批准

2014-06-01

科室
- - 订阅+
  - 更多科室
工具
服务